Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.52 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.52 |
| ▸ | MET | P08581 | 4/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 4/20 | 0.48 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.44 |
| ▸ | RET | P07949 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5830590 | 1.00 | KDR (0.52) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL6323692 | 0.92 | MET (0.56) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL6323687 | 0.92 | MET (0.56) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL5830890 | 0.92 | KDR (0.51) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL5830205 | 0.92 | KDR (0.51) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL5830520 | 0.91 | KDR (0.51) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL5830526 | 0.91 | KDR (0.51) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL16090377 | 0.91 | MET (0.54) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL6321868 | 0.90 | KDR (0.52) | KDRFGFR1METPTK2BMEN1 | |
| SCHEMBL6320753 | 0.90 | KDR (0.57) | KDRFGFR1METPTK2BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010048273-A2 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-7053086-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2004-05-20 | — | — | US | disclosed |
| US-6635640-B2 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | SUGEN, INC. | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160082015-A1 | METHODS, COMPOSITIONS AND KITS FOR PROMOTING MOTOR NEURON SURVIVAL AND TREATING AND DIAGNOSING NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SOD1, NEFM | KDR 4431/4885FGFR1 4574/4885MET 4540/4885 |
| US-20020187978-A1 | 4-Heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | KDR 1114/4885FGFR1 785/4885MET 1991/4885 |
| US-20040097497-A1 | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | CDK2, CDK20, CDK3 | KDR 1114/4885FGFR1 785/4885MET 1991/4885 |
| US-20120010178-A1 | METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, CLN6, SNCA | KDR 4776/4885FGFR1 4449/4885MET 4418/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | KDR 4866/4885FGFR1 4760/4885MET 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.